BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol 2017;14:203-17. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 221] [Cited by in F6Publishing: 211] [Article Influence: 36.8] [Reference Citation Analysis]
Number Citing Articles
1 Wu X, Wang Z, Luo L, Shu D, Wang K. Metabolomics in hepatocellular carcinoma: From biomarker discovery to precision medicine. Front Med Technol 2022;4:1065506. [PMID: 36688143 DOI: 10.3389/fmedt.2022.1065506] [Reference Citation Analysis]
2 Halfdanarson TR, Sonbol MB, Starr JS. Hepatobiliary carcinomas. Cardio-Oncology Practice Manual : a Companion to Braunwald 's Heart Disease 2023. [DOI: 10.1016/b978-0-323-68135-3.00051-9] [Reference Citation Analysis]
3 Wang F, Chen Q, Chen Y, Zhu Y, Zhang Y, Cao D, Zhou W, Liang X, Yang Y, Lin L, Hu H. A novel multimodal deep learning model for preoperative prediction of microvascular invasion and outcome in hepatocellular carcinoma. Eur J Surg Oncol 2023;49:156-64. [PMID: 36333180 DOI: 10.1016/j.ejso.2022.08.036] [Reference Citation Analysis]
4 Jin X, Ma X, Zhao D, Yang L, Ma N. Immune microenvironment and therapeutic progress of recurrent hepatocellular carcinoma after liver transplantation. Transl Oncol 2023;28:101603. [PMID: 36542991 DOI: 10.1016/j.tranon.2022.101603] [Reference Citation Analysis]
5 Liu HF, Zhang YZ, Wang Q, Zhu ZH, Xing W. A nomogram model integrating LI-RADS features and radiomics based on contrast-enhanced magnetic resonance imaging for predicting microvascular invasion in hepatocellular carcinoma falling the Milan criteria. Transl Oncol 2023;27:101597. [PMID: 36502701 DOI: 10.1016/j.tranon.2022.101597] [Reference Citation Analysis]
6 Liu P, Wang X, Liu H, Wang S, Xu Q, Wang L, Xu X, Cai J. Sirolimus improves the prognosis of liver recipients with hepatocellular carcinoma: A single-center experience. Hepatobiliary & Pancreatic Diseases International 2022. [DOI: 10.1016/j.hbpd.2022.11.010] [Reference Citation Analysis]
7 Wu S, Li Z, Yao C, Dong S, Gao J, Ke S, Zhu R, Huang S, Wang S, Xu L, Ye C, Kong J, Sun W. Progression of hepatocellular carcinoma after radiofrequency ablation: Current status of research. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1032746] [Reference Citation Analysis]
8 Liu Y, Yan P, Bin Y, Qin X, Wu Z. Neutrophil extracellular traps and complications of liver transplantation. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1054753] [Reference Citation Analysis]
9 Roushansarai NS, Pascher A, Becker F. Innate Immune Cells during Machine Perfusion of Liver Grafts-The Janus Face of Hepatic Macrophages. J Clin Med 2022;11. [PMID: 36431146 DOI: 10.3390/jcm11226669] [Reference Citation Analysis]
10 Knavel Koepsel EM, Smolock AR, Pinchot JW, Kim CY, Ahmed O, Chamarthy MR, Hecht EM, Hwang GL, Kaplan DE, Luh JY, Marrero JA, Monroe EJ, Poultsides GA, Scheidt MJ, Hohenwalter EJ. ACR Appropriateness Criteria® Management of Liver Cancer: 2022 Update. Journal of the American College of Radiology 2022;19:S390-S408. [DOI: 10.1016/j.jacr.2022.09.005] [Reference Citation Analysis]
11 Yang D, Su Y, Zhao F, Hu Y, Zhao K, Xiong X, Zhu M, Pei J, Ding Y. Low-grade hepatocellular carcinoma characteristics, a practical nomogram and risk stratification system: a SEER population-based study. Expert Rev Gastroenterol Hepatol 2022;16:1115-23. [PMID: 36412566 DOI: 10.1080/17474124.2022.2150610] [Reference Citation Analysis]
12 Guan F, Ding Y, He Y, Li L, Yang X, Wang C, Hu M. Involvement of adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 in diallyl trisulfide-induced cytotoxicity in hepatocellular carcinoma cells. Korean J Physiol Pharmacol 2022;26:457-68. [PMID: 36302621 DOI: 10.4196/kjpp.2022.26.6.457] [Reference Citation Analysis]
13 Cheng HY, Ho CM, Hsiao CY, Ho MC, Wu YM, Lee PH, Hu RH. Interval dynamics of transplantability for hepatocellular carcinoma after primary curative resection: risk factors for nontransplantable recurrence. HPB (Oxford) 2022:S1365-182X(22)01635-5. [PMID: 36376221 DOI: 10.1016/j.hpb.2022.10.010] [Reference Citation Analysis]
14 Dennis C, Prince DS, Moayed-alaei L, Remash D, Carr-boyd E, Bowen DG, Strasser SI, Crawford M, Pulitano C, Kench J, Mccaughan GW, Mckenzie C, Liu K. Association between vessels that encapsulate tumour clusters vascular pattern and hepatocellular carcinoma recurrence following liver transplantation. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.997093] [Reference Citation Analysis]
15 Becchetti C, Dirchwolf M, Schropp J, Magini G, Müllhaupt B, Immer F, Dufour JF, Banz V, Berzigotti A, Bosch J; Swiss Transplant Cohort Study. Use of statins after liver transplantation is associated with improved survival: results of a nationwide study. Aliment Pharmacol Ther 2022;56:1194-204. [PMID: 35979872 DOI: 10.1111/apt.17192] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
16 Reivell V, Hagman H, Haux J, Jorns C, Lindnér P, Taflin H. SOULMATE: the Swedish study of liver transplantation for isolated colorectal cancer liver metastases not suitable for operation or ablation, compared to best established treatment-a randomized controlled multicenter trial. Trials 2022;23:831. [PMID: 36180944 DOI: 10.1186/s13063-022-06778-9] [Reference Citation Analysis]
17 Sha M, Chen C, Shen C, Jeong S, Sun H, Xu N, Hang H, Cao J, Tong Y. Clinical analysis of deceased donor liver transplantation in the treatment of hepatocellular carcinoma with segmental portal vein tumor thrombus: A long-term real-world study. Front Oncol 2022;12:971532. [DOI: 10.3389/fonc.2022.971532] [Reference Citation Analysis]
18 Sposito C, Citterio D, Virdis M, Battiston C, Droz Dit Busset M, Flores M, Mazzaferro V. Therapeutic strategies for post-transplant recurrence of hepatocellular carcinoma. World J Gastroenterol 2022; 28(34): 4929-4942 [DOI: 10.3748/wjg.v28.i34.4929] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Jin X, Zhang K, Fang T, Zeng X, Yan X, Tang J, Liang Z, Xie L, Zhao D. Low-dose PD-1 inhibitor combined with lenvatinib for preemptive treatment of recurrence after liver transplantation for hepatocellular carcinoma: Case report and literature review. Front Oncol 2022;12:951303. [DOI: 10.3389/fonc.2022.951303] [Reference Citation Analysis]
20 Allaire M, Bruix J, Korenjak M, Manes S, Maravic Z, Reeves H, Salem R, Sangro B, Sherman M. What to do about Hepatocellular Carcinoma: Recommendations for Health Authorities: An International Liver Cancer Association Advocacy Document. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100578] [Reference Citation Analysis]
21 Wang Z, Tian X, Wang C, Qi X, Gracia‐sancho J, Dong L. Transforming one organ into another to overcome challenges in tissue engineering. Portal Hypertension & Cirrhosis 2022;1:116-124. [DOI: 10.1002/poh2.26] [Reference Citation Analysis]
22 Ahmed F, Zakaria F, Enebong Nya G, Mouchli M. Sirolimus vs tacrolimus: Which one is the best therapeutic option for patients undergoing liver transplantation for hepatocellular carcinoma? World J Gastrointest Surg 2022; 14(8): 862-866 [DOI: 10.4240/wjgs.v14.i8.862] [Reference Citation Analysis]
23 Ju MR, Karalis JD, Chansard M, Augustine MM, Mortensen E, Wang SC, Porembka MR, Zeh HJ 3rd, Yopp AC, Polanco PM. Variation of Hepatocellular Carcinoma Treatment Patterns and Survival Across Geographic Regions in a Veteran Population. Ann Surg Oncol 2022. [PMID: 36018517 DOI: 10.1245/s10434-022-12390-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Lin J, Yang J, Lu J, Hao X, Liu J, Yan H, Li H, Guo Y, Gu Y, Cheng Q. Clinical Features of de Novo Lung Neuroendocrine Tumor after Liver Transplantation for Hepatocellular Carcinoma. J Anal Oncol 2022;11:24-32. [DOI: 10.30683/1927-7229.2022.11.04] [Reference Citation Analysis]
25 Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2022;42:2055-66. [PMID: 34780081 DOI: 10.1111/liv.15101] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
26 Wei L, Wang Z, Jing N, Lu Y, Yang J, Xiao H, Guo H, Sun S, Li M, Zhao D, Li X, Qi W, Zhang Y. Frontier progress of the combination of modern medicine and traditional Chinese medicine in the treatment of hepatocellular carcinoma. Chin Med 2022;17:90. [PMID: 35907976 DOI: 10.1186/s13020-022-00645-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Au K, Fung JY, Dai W, Chan AC, Lo C, Chok KS. Impact of Tumour Biology on Outcomes of Radical Therapy for Hepatocellular Carcinoma Oligo-Recurrence after Liver Transplantation. JCM 2022;11:4389. [DOI: 10.3390/jcm11154389] [Reference Citation Analysis]
28 Bae BK, Park HC, Yu JI, Yoo GS, Sinn DH, Choi MS, Oh JH. Trends in radiotherapy administration in the management of hepatocellular carcinoma: Analysis of a Korean tertiary hospital registry of hepatocellular carcinoma patients diagnosed between 2005 and 2017. Front Oncol 2022;12:928119. [DOI: 10.3389/fonc.2022.928119] [Reference Citation Analysis]
29 Zhang D, Feng D, He X, Zhang X, Li L, Li Z, Niu X, Zhuang Y, Liu Z, Gao X, Wang H. The Combination of AFP and “Up-To-Seven” Criteria May Be a Better Strategy for Liver Transplantation in Chinese Cirrhotic HCC Patients. Front Oncol 2022;12:959151. [DOI: 10.3389/fonc.2022.959151] [Reference Citation Analysis]
30 Sparrelid E, Thorsen T, Sauter C, Jorns C, Stål P, Nordin A, de Boer MT, Buis C, Yaqub S, Schultz NA, Larsen PN, Sallinen V, Line PD, Gilg S. Liver transplantation in patients with post-hepatectomy liver failure - A Northern European multicenter cohort study. HPB (Oxford) 2022;24:1138-44. [PMID: 35067465 DOI: 10.1016/j.hpb.2021.12.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Kornberg A, Kaschny L, Kornberg J, Friess H. Preoperative Prognostic Nutritional Index May Be a Strong Predictor of Hepatocellular Carcinoma Recurrence Following Liver Transplantation. JHC 2022;Volume 9:649-60. [DOI: 10.2147/jhc.s366107] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Song W, Xiong X, Ge W, Zhu H. Prognostic value of protein biomarkers in liver transplantation: A systematic review. Proteomics Clin Appl 2022;16:e2100038. [PMID: 35344271 DOI: 10.1002/prca.202100038] [Reference Citation Analysis]
33 Liao C, Cheng Y, Yu C, Tsang LL, Chen C, Hsu H, Chang W, Lim W, Chuang Y, Huang P, Ou H. A Scoring System for Predicting Microvascular Invasion in Hepatocellular Carcinoma Based on Quantitative Functional MRI. JCM 2022;11:3789. [DOI: 10.3390/jcm11133789] [Reference Citation Analysis]
34 Lin H, Peng J, Zhu T, Xiong M, Zhang R, Lei L. Exosomal miR-4800-3p Aggravates the Progression of Hepatocellular Carcinoma via Regulating the Hippo Signaling Pathway by Targeting STK25. Front Oncol 2022;12:759864. [PMID: 35756606 DOI: 10.3389/fonc.2022.759864] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Degroote H, Geerts A, Verhelst X, Van Vlierberghe H. Different Models to Predict the Risk of Recurrent Hepatocellular Carcinoma in the Setting of Liver Transplantation. Cancers (Basel) 2022;14:2973. [PMID: 35740638 DOI: 10.3390/cancers14122973] [Reference Citation Analysis]
36 Ilmer M, Guba MO. Liver Transplant Oncology: Towards Dynamic Tumor-Biology-Oriented Patient Selection. Cancers 2022;14:2662. [DOI: 10.3390/cancers14112662] [Reference Citation Analysis]
37 Sugawara Y, Hibi T. Liver transplantation for patients with hepatocellular carcinoma: Its current status and advances. Biosci Trends 2022. [PMID: 35613874 DOI: 10.5582/bst.2022.01199] [Reference Citation Analysis]
38 Fernández-de la Varga M, Del Pozo-Del Valle P, Béjar-Serrano S, López-Andújar R, Berenguer M, Prieto M, Montalvá E, Aguilera V. Good post-transplant outcomes using liver donors after circulatory death when applying strict selection criteria: A propensity-score matched-cohort study. Ann Hepatol 2022;27:100724. [PMID: 35643260 DOI: 10.1016/j.aohep.2022.100724] [Reference Citation Analysis]
39 Wu X, Ge L, Shen G, He Y, Xu Z, Li D, Mu C, Zhao L, Zhang W. 131I-Labeled Silk Fibroin Microspheres for Radioembolic Therapy of Rat Hepatocellular Carcinoma. ACS Appl Mater Interfaces 2022;14:21848-59. [PMID: 35507826 DOI: 10.1021/acsami.2c00211] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
40 Wei RL, Fan GH, Zhang CZ, Chen KC, Zhang WH, Li CB, Dong SY, Chen JL, Ling SB, Zheng SS, Xu X. Prognostic implication of early posttransplant hypercholesterolemia in liver transplantation for patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00123-0. [PMID: 35613994 DOI: 10.1016/j.hbpd.2022.05.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Yang Z, Chen W, Zhu H, Zhang L, Zhou K, Tang H, Sun R, Huang Y, Xie H, Zheng S, Jia C. Methylation site APC112043544 as a potential biomarker for post-transplant hepatocellular carcinoma recurrence. Future Oncol 2022. [PMID: 35502765 DOI: 10.2217/fon-2021-1608] [Reference Citation Analysis]
42 Zhang XF, Xue F, Bagante F, Ratti F, Marques HP, Silva S, Soubrane O, Lam V, Poultsides GA, Popescu I, Grigorie R, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Lv Y, Pawlik TM. Non-transplantable Recurrence After Resection for Transplantable Hepatocellular Carcinoma: Implication for Upfront Treatment Choice. J Gastrointest Surg 2022;26:1021-9. [PMID: 34797558 DOI: 10.1007/s11605-021-05206-8] [Reference Citation Analysis]
43 Herrero A, Boivineau L, Cassese G, Assenat E, Riviere B, Faure S, Bedoya JU, Panaro F, Guiu B, Navarro F, Pageaux GP. Progression of AFP SCORE is a Preoperative Predictive Factor of Microvascular Invasion in Selected Patients Meeting Liver Transplantation Criteria for Hepatocellular Carcinoma. Transpl Int 2022;35:10412. [PMID: 35401038 DOI: 10.3389/ti.2022.10412] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Holzner ML, Florman S, Schwartz ME, Tabrizian P. Outcomes of liver transplantation for nonalcoholic steatohepatitis-associated hepatocellular carcinoma. HPB (Oxford) 2022;24:470-7. [PMID: 34544629 DOI: 10.1016/j.hpb.2021.08.943] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
45 Lee HL, Lee SW, Jang JW, Bae SH, Choi JY, Yoon SK, Choi HJ, Na GH, You YK, Park IY, Kim DG. Anticancer Effect of Statins in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Liver Transpl 2022;28:397-406. [PMID: 34374192 DOI: 10.1002/lt.26258] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
46 Sousa Da Silva RX, Muellhaupt B, Dutkowski P, Clavien P. Liver transplantation for malignant liver tumors. iLIVER 2022;1:3-11. [DOI: 10.1016/j.iliver.2022.04.002] [Reference Citation Analysis]
47 Koh JH, Tan DJH, Ong Y, Lim WH, Ng CH, Tay PWL, Yong JN, Muthiah MD, Tan EX, Pang NQ, Kim BK, Syn N, Kow A, Goh BKP, Huang DQ. Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients. Hepatobiliary Surg Nutr 2022;11:78-93. [PMID: 35284509 DOI: 10.21037/hbsn-21-350] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
48 Merchant N, Peela S, Alam A, Nagaraju GP. Curcumin formulated nanoparticles for hepatocellular carcinoma. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3 2022. [DOI: 10.1016/b978-0-323-99283-1.00025-2] [Reference Citation Analysis]
49 Farooq A, Ahmed Z, Wert J, Jalil A, Yu J, Zaytsev V, Ahmad S. Updates on clinical trials for the management of hepatocellular carcinoma. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3 2022. [DOI: 10.1016/b978-0-323-99283-1.00013-6] [Reference Citation Analysis]
50 Mani H, Ali S, Ahmad S. Updates on the staging and treatment of hepatocellular carcinoma. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 2 2022. [DOI: 10.1016/b978-0-323-98807-0.00015-6] [Reference Citation Analysis]
51 Zhu F, Wang BR, Zhu ZF, Wang SQ, Chai CX, Shang D, Li M. Photodynamic therapy: A next alternative treatment strategy for hepatocellular carcinoma? World J Gastrointest Surg 2021; 13(12): 1523-1535 [DOI: 10.4240/wjgs.v13.i12.1523] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Wei J, Sun Z, Shi L, Hu S, Liu D, Wei H. Molecular Mechanism of Chrysin in Hepatocellular Carcinoma Treatment Based on Network Pharmacology and in Vitro Experiments. Natural Product Communications 2021;16:1934578X2110672. [DOI: 10.1177/1934578x211067294] [Reference Citation Analysis]
53 Wang A, Fang J, Ye S, Mao Q, Zhao Y, Cui C, Zhang Y, Feng Y, Li J, He L, Qiu L, Shi H. Assembly Transformation Jointly Driven by the LAP Enzyme and GSH Boosting Theranostic Capability for Effective Tumor Therapy. ACS Appl Mater Interfaces 2021;13:59787-802. [PMID: 34894664 DOI: 10.1021/acsami.1c21062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
54 Agarwal PD, Lucey MR. Management of hepatocellular carcinoma recurrence after liver transplantation. Ann Hepatol 2022;27:100654. [PMID: 34929349 DOI: 10.1016/j.aohep.2021.100654] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
55 Li C, Chen J, Li Y, Wu B, Ye Z, Tian X, Wei Y, Hao Z, Pan Y, Zhou H, Yang K, Fu Z, Xu J, Lu Y. 6-Phosphogluconolactonase Promotes Hepatocellular Carcinogenesis by Activating Pentose Phosphate Pathway. Front Cell Dev Biol 2021;9:753196. [PMID: 34765603 DOI: 10.3389/fcell.2021.753196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
56 Chen S, Ma W, Shen L, Wu Y, Qi H, Cao F, Huang T, Fan W. Recurrence Beyond the Milan Criteria of HBV-Related Single Hepatocellular Carcinoma of 2-3 cm: Comparison of Resection and Ablation. Front Oncol 2021;11:757149. [PMID: 34733791 DOI: 10.3389/fonc.2021.757149] [Reference Citation Analysis]
57 Huang A, Guo DZ, Wang YP, Yang GH, Sun QM, Zhang X, He YF, Song K, Huang XW, Yang XR, Fan J, Zhou J, Hu J. Plasma MicroRNA Panel Predicts Early Tumor Recurrence in Patients with Hepatocellular Carcinoma after Liver Transplantation. J Cancer 2021;12:7190-200. [PMID: 34729120 DOI: 10.7150/jca.59612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Mehta N, Frenette C, Tabrizian P, Hoteit M, Guy J, Parikh N, Ghaziani TT, Dhanasekaran R, Dodge JL, Natarajan B, Holzner ML, Frankul L, Chan W, Fobar A, Florman S, Yao FY. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. Gastroenterology 2021;161:1502-12. [PMID: 34331914 DOI: 10.1053/j.gastro.2021.07.033] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
59 Ferrer-Fàbrega J, Sampson-Dávila J, Forner A, Sapena V, Díaz A, Vilana R, Navasa M, Fondevila C, Miquel R, Ayuso C, García-Valdecasas JC, Bruix J, Reig M, Fuster J. Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. J Hepatol 2021;75:1154-63. [PMID: 34171433 DOI: 10.1016/j.jhep.2021.06.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
60 Chen Z, Wang T, Chen C, Hong X, Yu J, Ma Y, Guo Y, Huang C, He X, Ju W, Chen M. Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma. J Oncol 2021;2021:7776389. [PMID: 34712326 DOI: 10.1155/2021/7776389] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Gan K, Li Z, Bao S, Fang Y, Wang T, Jin L, Ma M, Deng L, Peng Y, Li N, Zeng Z, Huang H. Clinical outcomes after ABO-incompatible liver transplantation: A systematic review and meta-analysis. Transpl Immunol 2021;69:101476. [PMID: 34601097 DOI: 10.1016/j.trim.2021.101476] [Reference Citation Analysis]
62 Pozo-laderas J, Guler I, Rodríguez-perálvarez M, Robles J, Mula A, López-cillero P, de la Fuente C. Early postoperative mortality in liver transplant recipients involving indications other than hepatocellular carcinoma. A retrospective cohort study. Medicina Intensiva 2021;45:395-410. [DOI: 10.1016/j.medin.2020.02.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Rui T, Zhang X, Feng S, Huang H, Zhan S, Xie H, Zhou L, Zheng S, Ling Q. MiR-516a-3p is a Novel Mediator of Hepatocellular Carcinoma Oncogenic Activity and Cellular Metabolism. Engineering 2021. [DOI: 10.1016/j.eng.2021.07.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
64 Pelizzaro F, Gambato M, Gringeri E, Vitale A, Cillo U, Farinati F, Burra P, Russo FP. Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers (Basel) 2021;13:4882. [PMID: 34638365 DOI: 10.3390/cancers13194882] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
65 Rinaldi L, Vetrano E, Rinaldi B, Galiero R, Caturano A, Salvatore T, Sasso FC. HCC and Molecular Targeting Therapies: Back to the Future. Biomedicines 2021;9:1345. [PMID: 34680462 DOI: 10.3390/biomedicines9101345] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
66 Pozo-Laderas JC, Guler I, Rodríguez-Perálvarez M, Robles JC, Mula A, López-Cillero P, de la Fuente C. Early postoperative mortality in liver transplant recipients involving indications other than hepatocellular carcinoma. A retrospective cohort study. Med Intensiva (Engl Ed) 2021;45:395-410. [PMID: 34563340 DOI: 10.1016/j.medine.2020.02.004] [Reference Citation Analysis]
67 Zhao Y, Liu Y, Zhou L, Du GS, He Q. Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(9): 953-966 [PMID: 34621472 DOI: 10.4240/wjgs.v13.i9.953] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Birgin E, Kaslow SR, Hetjens S, Correa-Gallego C, Rahbari NN. Minimally Invasive versus Open Liver Resection for Stage I/II Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4800. [PMID: 34638285 DOI: 10.3390/cancers13194800] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
69 Li M, Tang Y, Wang D, Zhai X, Shen H, Zhong C, Yao M, Jin A, Zhou Z, Zhou S, Fan J, Ling CQ, Ling C. Sphingosine-1-phosphate transporter spinster homolog 2 is essential for iron-regulated metastasis of hepatocellular carcinoma. Mol Ther 2021:S1525-0016(21)00467-6. [PMID: 34547466 DOI: 10.1016/j.ymthe.2021.09.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
70 Xie YL, Yang Z, Feng X, Yang Q, Ye LS, Li XB, Tang H, Zhang YC, Liu W, Tong Zhang, Fu BS, Yi SH, Yang Y, Chen GH. Association of phenotypic transformation of circulating tumor cells and early recurrence in patients with hepatocellular carcinoma following liver transplantation. Asian J Surg 2021:S1015-9584(21)00477-2. [PMID: 34426060 DOI: 10.1016/j.asjsur.2021.07.058] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
71 Zhang W, Liu Z, Chen J, Dong S, Cen B, Zheng S, Xu X. A preoperative model for predicting microvascular invasion and assisting in prognostic stratification in liver transplantation for HCC regarding empirical criteria. Transl Oncol 2021;14:101200. [PMID: 34399173 DOI: 10.1016/j.tranon.2021.101200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Yacoub JH, Hsu CC, Fishbein TM, Mauro D, Moon A, He AR, Bashir MR, Burke LMB. Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation-part one: curative intention. Abdom Radiol (NY) 2021;46:3528-39. [PMID: 33835223 DOI: 10.1007/s00261-021-03069-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Dumortier J, Besch C, Moga L, Coilly A, Conti F, Corpechot C, Bello AD, Faitot F, Francoz C, Hilleret MN, Houssel-Debry P, Jezequel C, Lavayssière L, Neau-Cransac M, Erard-Poinsot D, de Lédinghen V, Bourlière M, Bureau C, Ganne-Carrié N. NON-INVASIVE DIAGNOSIS AND FOLLOW-UP IN LIVER TRANSPLANTATION. Clin Res Hepatol Gastroenterol 2021;:101774. [PMID: 34332131 DOI: 10.1016/j.clinre.2021.101774] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Rodríguez-Perálvarez M, Gómez-Bravo MÁ, Sánchez-Antolín G, De la Rosa G, Bilbao I, Colmenero J; Spanish Society of Liver Transplantation (SETH) Consensus Panel. Expanding Indications of Liver Transplantation in Spain: Consensus Statement and Recommendations by the Spanish Society of Liver Transplantation. Transplantation 2021;105:602-7. [PMID: 32345868 DOI: 10.1097/TP.0000000000003281] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
75 Hafeez Bhatti AB, Qureshi AI, Tahir R, Almas T, Rana A. Liver transplantation for hepatocellular carcinoma: Improving eligibility without compromising outcomes. Ann Med Surg (Lond) 2021;68:102552. [PMID: 34295467 DOI: 10.1016/j.amsu.2021.102552] [Reference Citation Analysis]
76 Perisetti A, Goyal H, Yendala R, Thandassery RB, Giorgakis E. Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements. World J Gastroenterol 2021; 27(24): 3466-3482 [PMID: 34239263 DOI: 10.3748/wjg.v27.i24.3466] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
77 Voskanyan SE, Naidenov EV, Artemiev AI, Kolyshev IY, Zabezhinsky DA, Gubarev KK, Rudakov VS, Shabalin MV, Sushkov AI, Popov MV, Svetlakova DS, Maltseva AP, Muktarzhan M, Sadykhov Z, Vidmer EV. Long-term results of liver transplantation for hepatocellular cancer. Ann hir gepatol 2021;26:68-82. [DOI: 10.16931/10.16931/1995-5464.2021-2-68-82] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Cusumano C, De Carlis L, Centonze L, Lesourd R, Levi Sandri GB, Lauterio A, De Carlis R, Ferla F, Di Sandro S, Camus C, Jézéquel C, Bardou-Jacquet E, Rayar M. Advanced donor age does not increase risk of hepatocellular carcinoma recurrence after liver transplantation: a retrospective two-centre analysis using competing risk analysis. Transpl Int 2021. [PMID: 34145653 DOI: 10.1111/tri.13950] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
79 Wang J, Li Y, Wang R, Han C, Xu S, You T, Li Y, Xia J, Xu X, Wang D, Tang H, Yang C, Chen X, Peng Z. A Fully Automated and Integrated Microfluidic System for Efficient CTC Detection and Its Application in Hepatocellular Carcinoma Screening and Prognosis. ACS Appl Mater Interfaces 2021;13:30174-86. [PMID: 34142547 DOI: 10.1021/acsami.1c06337] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
80 Liao W, Fan L, Zheng Z, Liu H, Deng H, Li M, Liu F, Yang A. Ziyuglycoside II exerts antiproliferative and antimetastasis effects on hepatocellular carcinoma cells. Anticancer Drugs 2020;31:819-27. [PMID: 32097137 DOI: 10.1097/CAD.0000000000000918] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
81 Eom JA, Kwon GH, Kim NY, Park EJ, Won SM, Jeong JJ, Raja G, Gupta H, Asmelash Gebru Y, Sharma S, Choi YR, Kim HS, Yoon SJ, Hyun JY, Jeong MK, Park HJ, Min BH, Choi MR, Kim DJ, Suk KT. Diet-Regulating Microbiota and Host Immune System in Liver Disease. Int J Mol Sci 2021;22:6326. [PMID: 34199182 DOI: 10.3390/ijms22126326] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
82 Yang Y, Sun M, Yao W, Wang F, Li X, Wang W, Li J, Gao Z, Qiu L, You R, Yang C, Ba Q, Wang H. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib. J Immunother Cancer 2020;8:e000317. [PMID: 32179631 DOI: 10.1136/jitc-2019-000317] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 20.5] [Reference Citation Analysis]
83 Chen M, Chen Z, Lin X, Hong X, Ma Y, Huang C, He X, Ju W. Application of ischaemia-free liver transplantation improves prognosis of patients with steatotic donor livers - a retrospective study.Transpl Int. 2021;34:1261-1270. [PMID: 33484201 DOI: 10.1111/tri.13828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
84 Jung D, Hwang S, Song G. Selection criteria of living donor liver transplantation for hepatocellular carcinoma developed in Korean transplant centers. Ann Liver Transplant 2021;1:48-66. [DOI: 10.52604/alt.11.0007] [Reference Citation Analysis]
85 Jung D, Hwang S, Song G. Selection criteria of living donor liver transplantation for hepatocellular carcinoma developed in Korean transplant centers. Ann Liver Transplant 2021;1:29-47. [DOI: 10.52604/alt.21.0005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
86 Panayotova G, Lunsford KE, Latt NL, Paterno F, Guarrera JV, Pyrsopoulos N. Expanding indications for liver transplantation in the era of liver transplant oncology. World J Gastrointest Surg 2021; 13(5): 392-405 [PMID: 34122730 DOI: 10.4240/wjgs.v13.i5.392] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
87 Lerut J, Foguenne M, Lai Q. Hepatocellular cancer selection systems and liver transplantation: from the tower of babel to an ideal comprehensive score. Updates Surg 2021. [PMID: 34003479 DOI: 10.1007/s13304-021-01078-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
88 Weller A, Seyfried T, Ahrens N, Baier-Kleinhenz L, Schlitt HJ, Peschel G, Graf BM, Sinner B. Cell Salvage During Liver Transplantation for Hepatocellular Carcinoma: A Retrospective Analysis of Tumor Recurrence Following Irradiation of the Salvaged Blood. Transplant Proc 2021;53:1639-44. [PMID: 33994180 DOI: 10.1016/j.transproceed.2021.03.025] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
89 Jiang Z, Jiang Q, Fang X, Wang P, Que W, Li H, Yu Y, Liu X, Wang C, Zhong L. Recipient C7 rs9292795 genotype and the risk of hepatocellular carcinoma recurrence after orthotopic liver transplantation in a Han Chinese population. BMC Cancer 2021;21:521. [PMID: 33964921 DOI: 10.1186/s12885-021-08269-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
90 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
91 Ye F, Huang W, Xue Y, Tang E, Wang M, Shi F, Wei D, Han Y, Chen P, Zhang X, Yu D. Serum Levels of ITGBL1 as an Early Diagnostic Biomarker for Hepatocellular Carcinoma with Hepatitis B Virus Infection. J Hepatocell Carcinoma 2021;8:285-300. [PMID: 33948441 DOI: 10.2147/JHC.S306966] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
92 Hu J, Cai D, Zhao Z, Zhong GC, Gong J. Suppression of Heterogeneous Nuclear Ribonucleoprotein C Inhibit Hepatocellular Carcinoma Proliferation, Migration, and Invasion via Ras/MAPK Signaling Pathway. Front Oncol 2021;11:659676. [PMID: 33937074 DOI: 10.3389/fonc.2021.659676] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
93 Renner P, Da Silva T, Schnitzbauer AA, Verloh N, Schlitt HJ, Geissler EK. Hepatocellular carcinoma progression during bridging before liver transplantation. BJS Open 2021;5:zrab005. [PMID: 33839747 DOI: 10.1093/bjsopen/zrab005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
94 Yang Z, Zhang L, Zhu H, Zhou K, Wang H, Wang Y, Su R, Guo D, Zhou L, Xu X, Song P, Zheng S, Xie H. Nanoparticle formulation of mycophenolate mofetil achieves enhanced efficacy against hepatocellular carcinoma by targeting tumour-associated fibroblast. J Cell Mol Med 2021;25:3511-23. [PMID: 33713546 DOI: 10.1111/jcmm.16434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
95 Sapisochin G, Hibi T, Toso C, Man K, Berenguer M, Heimbach J, Greten TF, Pugh TJ, Dawson LA, Mazzaferro V. Transplant Oncology in Primary and Metastatic Liver Tumors: Principles, Evidence, and Opportunities. Ann Surg 2021;273:483-93. [PMID: 33065633 DOI: 10.1097/SLA.0000000000004071] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
96 Zou ZM, Chang DH, Liu H, Xiao YD. Current updates in machine learning in the prediction of therapeutic outcome of hepatocellular carcinoma: what should we know? Insights Imaging 2021;12:31. [PMID: 33675433 DOI: 10.1186/s13244-021-00977-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
97 Wang PX, Xu Y, Sun YF, Cheng JW, Zhou KQ, Wu SY, Hu B, Zhang ZF, Guo W, Cao Y, Huang XW, Zhou J, Fan J, Yang XR. Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation. Liver Int 2021;41:562-73. [PMID: 33205544 DOI: 10.1111/liv.14734] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
98 Zhang J, Yu Z, Li H, Yi S, Liu W, Yang Y, Wang G. Severe bile duct complication after yttrium-90 radioembolization therapy in a patient with recurrent hepatocellular carcinoma after liver transplantation: A case report. Liver Research 2021;5:33-5. [DOI: 10.1016/j.livres.2020.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
99 Ma E, Li J, Xing H, Li R, Shen C, Zhang Q, Ma Z, Tao Y, Qin L, Zhao J, Wang Z. Development of a predictive nomogram for early recurrence of hepatocellular carcinoma in patients undergoing liver transplantation. Ann Transl Med 2021;9:468. [PMID: 33850865 DOI: 10.21037/atm-21-334] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
100 Ahmed O, Vachharajani N, Chang SH, Park Y, Khan AS, Chapman WC, Doyle MB. Access to Liver Transplantation for Hepatocellular Carcinoma: Does Candidate Age Matter? J Am Coll Surg 2021;233:140-51. [PMID: 33652155 DOI: 10.1016/j.jamcollsurg.2021.01.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
101 Gorgen A, Galvin Z, Huang AC, Vinaixa C, O'Rourke JM, Francoz C, Hansen BE, Durand F, Elsharkawy AM, Shah T, Berenguer M, Rubin A, Calatayud D, Mehta N, Terrault NA, Lilly LB, Selzner N, Sapisochin G. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study. Transplantation 2020;104:2087-96. [PMID: 31978002 DOI: 10.1097/TP.0000000000003115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
102 Chen S, Wu Y, Qi H, Shen L, Ma W, Cao F, Diao Y, Wang T, Ou S, Fan W. Single-nodule hepatitis B virus-associated hepatocellular carcinoma smaller than 3 cm: two phenotypes defined by cluster analysis and their association with the outcome of ablation as the first-line therapy. Int J Hyperthermia 2021;38:120-9. [PMID: 33541160 DOI: 10.1080/02656736.2021.1876930] [Reference Citation Analysis]
103 Chen Y, Wang G, Xu H, Wang H, Bai D. Identification of a Novel Metastasis-Related miRNAs-Based Signature for Predicting the Prognosis of Hepatocellular Carcinoma. J Oncol 2021;2021:6629633. [PMID: 33603784 DOI: 10.1155/2021/6629633] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
104 Lee SK, Jang JW, Nam H, Sung PS, Kim HY, Kwon JH, Lee SW, Song DS, Kim CW, Song MJ, Choi HJ, You YK, Bae SH, Choi JY, Yoon SK. Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation. Hepatol Int 2021;15:137-45. [PMID: 33496932 DOI: 10.1007/s12072-020-10131-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
105 Chen Y, Mu S, Wang J, Wu A. Chronic severe hepatitis and preoperative creatinine are independent risk factors for acute kidney injury after liver transplantation. Ann Transl Med 2020;8:1663. [PMID: 33490175 DOI: 10.21037/atm-20-7680] [Reference Citation Analysis]
106 Hue JJ, Rocha FG, Ammori JB, Hardacre JM, Rothermel LD, Chavin KD, Winter JM, Ocuin LM. A comparison of surgical resection and liver transplantation in the treatment of intrahepatic cholangiocarcinoma in the era of modern chemotherapy: An analysis of the National Cancer Database. J Surg Oncol 2021;123:949-56. [PMID: 33400841 DOI: 10.1002/jso.26370] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
107 熊 凌. Does Fibrosis Influence Survival after Liver Transplantation? Evidence from the SEER Database. ACM 2021;11:5594-5605. [DOI: 10.12677/acm.2021.1111829] [Reference Citation Analysis]
108 Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52:1898-1907. [PMID: 33268834 DOI: 10.1038/s12276-020-00527-1] [Cited by in Crossref: 65] [Cited by in F6Publishing: 69] [Article Influence: 21.7] [Reference Citation Analysis]
109 Petrowsky H, Fritsch R, Guckenberger M, De Oliveira ML, Dutkowski P, Clavien PA. Modern therapeutic approaches for the treatment of malignant liver tumours. Nat Rev Gastroenterol Hepatol 2020;17:755-72. [PMID: 32681074 DOI: 10.1038/s41575-020-0314-8] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 23.0] [Reference Citation Analysis]
110 Chagas AL, Mattos AA, Diniz MA, Felga GEG, Boin IFSF, Silva RCMA, Silva RF, Garcia JHP, Lima AS, Coelho JCU, Bittencourt PL, Alves VAF, D'Albuquerque LAC, Carrilho FJ; Brazilian HCC Study Group. Impact of Brazilian expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a multicenter study. Ann Hepatol 2021;22:100294. [PMID: 33276136 DOI: 10.1016/j.aohep.2020.100294] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
111 Yu H, Bai Y, Xu C, He X, Liu Q, Ma D, A Y. The tissue expression levels of SUMO1P 3 may be a reliable prognostic biomarker to predict the clinical outcomes in patients with HCC. Medicine (Baltimore) 2020;99:e21291. [PMID: 33181633 DOI: 10.1097/MD.0000000000021291] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
112 Sladky VC, Knapp K, Szabo TG, Braun VZ, Bongiovanni L, van den Bos H, Spierings DC, Westendorp B, Curinha A, Stojakovic T, Scharnagl H, Timelthaler G, Tsuchia K, Pinter M, Semmler G, Foijer F, de Bruin A, Reiberger T, Rohr-Udilova N, Villunger A. PIDDosome-induced p53-dependent ploidy restriction facilitates hepatocarcinogenesis. EMBO Rep 2020;21:e50893. [PMID: 33225610 DOI: 10.15252/embr.202050893] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
113 Bhatti ABH, Hassan M, Rana A, Khan NY, Khan ZA, Zia HH. Risk Score Model for Liver Transplant Outcomes after Preoperative Locoregional Therapy for Hepatocellular Carcinoma. J Gastrointest Cancer 2020. [PMID: 33184772 DOI: 10.1007/s12029-020-00554-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
114 Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720. [PMID: 33442540 DOI: 10.1159/000509424] [Cited by in Crossref: 198] [Cited by in F6Publishing: 204] [Article Influence: 66.0] [Reference Citation Analysis]
115 Chen X, Xu J, Wang P, Shang L, Guo J, Huang L, Jiang YA, Chen J, Chen H, Shang Y, Zhang Q. Metallophosphoesterase 1, a novel candidate gene in hepatocellular carcinoma malignancy and recurrence. Cancer Biol Ther 2020;21:1005-13. [PMID: 33054568 DOI: 10.1080/15384047.2020.1824480] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
116 Pan YX, Fu YZ, Hu DD, Long Q, Wang JC, Xi M, Liu SL, Xu L, Liu MZ, Chen MS, Zhang YJ. Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-Analysis. Front Oncol. 2020;10:1639. [PMID: 33194569 DOI: 10.3389/fonc.2020.01639] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
117 Berenguer M, Burra P, Ghobrial M, Hibi T, Metselaar H, Sapisochin G, Bhoori S, Kwan Man N, Mas V, Ohira M, Sangro B, van der Laan LJW. Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. Transplantation 2020;104:1143-9. [PMID: 32217940 DOI: 10.1097/TP.0000000000003196] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
118 Moeckli B, Ivanics T, Claasen M, Toso C, Sapisochin G. Recent developments and ongoing trials in transplant oncology. Liver Int 2020;40:2326-44. [PMID: 33021344 DOI: 10.1111/liv.14621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
119 Franken LC, Vuijk FA, Soer EC, Roos E, Erdmann JI, Hooijer GKJ, Vahrmeijer AL, Gambhir SS, van Gulik TM, Sarasqueta AF, Verheij J, Swijnenburg RJ. Expression of integrin ανβ6 differentiates perihilar cholangiocarcinoma (PHC) from benign disease mimicking PHC. Eur J Surg Oncol 2021;47:628-34. [PMID: 33069505 DOI: 10.1016/j.ejso.2020.09.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
120 Kong F, Jin M, Cao D, Jia Z, Liu Y, Jiang J. Galectin-3 not Galectin-9 as a candidate prognosis marker for hepatocellular carcinoma. PeerJ 2020;8:e9949. [PMID: 32995093 DOI: 10.7717/peerj.9949] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
121 Patel K, Lamm R, Altshuler P, Dang H, Shah AP. Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy. Int J Mol Sci 2020;21:E6757. [PMID: 32942580 DOI: 10.3390/ijms21186757] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
122 Sultan LR, D'souza JC, Karmacharya MB, Hunt SJ, Brice AK, Gade T, Wood AK, Sehgal CM. Dose-dependent effects of ultrasound therapy on hepatocellular carcinoma. 2020 IEEE International Ultrasonics Symposium (IUS) 2020. [DOI: 10.1109/ius46767.2020.9251660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
123 Chen Z, Lin X, Chen C, Chen Y, Zhao Q, Wu L, Wang D, Ma Y, Ju W, Chen M, He X. Analysis of preoperative circulating tumor cells for recurrence in patients with hepatocellular carcinoma after liver transplantation. Ann Transl Med. 2020;8:1067. [PMID: 33145286 DOI: 10.21037/atm-20-2751] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
124 Silverstein J, Roll G, Dodge JL, Grab JD, Yao FY, Mehta N. Donation After Circulatory Death Is Associated With Similar Posttransplant Survival in All but the Highest-Risk Hepatocellular Carcinoma Patients. Liver Transpl 2020;26:1100-11. [PMID: 32531867 DOI: 10.1002/lt.25819] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
125 Sanduzzi-Zamparelli M, Rimola J, Montironi C, Nunes V, Alves VAF, Sapena V, da Fonseca LG, Forner A, Carrilho FJ, Díaz A, Fuster C, Ferrer J, Fuster J, Ayuso C, Solé M, Bruix J, Reig M; Epithelioid Hemangioendothelioma International Network (EHIN). Hepatic epithelioid hemangioendothelioma: An international multicenter study. Dig Liver Dis 2020;52:1041-6. [PMID: 32535084 DOI: 10.1016/j.dld.2020.05.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
126 Cacicedo ML, Medina-Montano C, Kaps L, Kappel C, Gehring S, Bros M. Role of Liver-Mediated Tolerance in Nanoparticle-Based Tumor Therapy. Cells 2020;9:E1985. [PMID: 32872352 DOI: 10.3390/cells9091985] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
127 Sokolich J, Buggs J, LaVere M, Robichaux K, Rogers E, Nyce S, Kumar A, Bowers V. HCC Liver Transplantation Wait List Dropout Rates Before and After the Mandated 6-Month Wait Time. Am Surg 2020;86:1592-5. [PMID: 32812771 DOI: 10.1177/0003134820942165] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
128 Wei N, Wu Z, Lu D, Xiao J, Zhou C, Chu S, Lv W. Expression of MMP-2 in residual VX2 liver tumor after transcatheter arterial embolization combined with portal venous embolization in an animal model. J Interv Med 2020;3:167-73. [PMID: 34805929 DOI: 10.1016/j.jimed.2020.08.006] [Reference Citation Analysis]
129 Bhatti ABH, Qureshi AI, Tahir R, Dar FS, Khan NY, Zia HH, Riyaz S, Rana A. When to call it off: defining transplant candidacy limits in liver donor liver transplantation for hepatocellular carcinoma. BMC Cancer. 2020;20:754. [PMID: 32787864 DOI: 10.1186/s12885-020-07238-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
130 Yang Z, Wang S, Tian XY, Xie QF, Zhuang L, Li QY, Chen CZ, Zheng SS. Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience. Hepatobiliary Pancreat Dis Int 2020;19:365-70. [PMID: 32553774 DOI: 10.1016/j.hbpd.2020.06.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
131 Ma D, Gao X, Liu Z, Lu X, Ju H, Zhang N. Exosome-transferred long non-coding RNA ASMTL-AS1 contributes to malignant phenotypes in residual hepatocellular carcinoma after insufficient radiofrequency ablation. Cell Prolif 2020;53:e12795. [PMID: 32722884 DOI: 10.1111/cpr.12795] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
132 Halazun KJ, Sapisochin G, von Ahrens D, Agopian VG, Tabrizian P. Predictors of outcome after liver transplantation for hepatocellular carcinoma (HCC) beyond Milan criteria. Int J Surg. 2020;82S:61-69. [PMID: 32707331 DOI: 10.1016/j.ijsu.2020.07.029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
133 Hafeez Bhatti AB, Tahir R, Qureshi NR, Mamoon N, Khan NY, Zia HH. Living donor liver transplantation for intra hepatic cholangiocarcinoma. Ann Med Surg (Lond) 2020;57:82-4. [PMID: 32728435 DOI: 10.1016/j.amsu.2020.07.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
134 Liu ZG, Chen XH, Yu ZJ, Lv J, Ren ZG. Recent progress in pulsed electric field ablation for liver cancer. World J Gastroenterol 2020; 26(24): 3421-3431 [PMID: 32655266 DOI: 10.3748/wjg.v26.i24.3421] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
135 Liu X, Hou Y, Wang X, Yu L, Wang X, Jiang L, Yang Z. Machine learning-based development and validation of a scoring system for progression-free survival in liver cancer. Hepatol Int 2020;14:567-76. [DOI: 10.1007/s12072-020-10046-w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
136 Pagano D, Barbàra M, Seidita A, Cintorino D, di Francesco F, Petridis I, Calamia S, Russelli G, Gruttadauria S. Impact of Extended-Criteria Donor Liver Grafts on Benchmark Metrics of Clinical Outcome After Liver Transplantation: A Single Center Experience. Transplantation Proceedings 2020;52:1588-92. [DOI: 10.1016/j.transproceed.2020.02.050] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
137 Sladky V, Knapp K, Szabo TG, Bongiovanni L, van den Bos H, Spierings DC, Westendorp B, Stojakovic T, Scharnagl H, Timelthaler G, Tsuchia K, Pinter M, Foijer F, de Bruin A, Reiberger T, Rohr-udilova N, Villunger A. PIDDosome-induced p53-activation for ploidy restriction facilitates hepatocarcinogenesis.. [DOI: 10.1101/2020.05.13.092486] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
138 da Silva EFG, Lima KG, Krause GC, Haute GV, Pedrazza L, Catarina AV, Gassen RB, de Souza Basso B, Dias HB, Luft C, Garcia MCR, Costa BP, Antunes GL, Basso LA, Donadio MVF, Machado P, de Oliveira JR. CPBMF65, a synthetic human uridine phosphorylase-1 inhibitor, reduces HepG2 cell proliferation through cell cycle arrest and senescence. Invest New Drugs 2020;38:1653-63. [DOI: 10.1007/s10637-020-00941-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
139 Bonferoni MC, Gavini E, Rassu G, Maestri M, Giunchedi P. Chitosan Nanoparticles for Therapy and Theranostics of Hepatocellular Carcinoma (HCC) and Liver-Targeting. Nanomaterials (Basel) 2020;10:E870. [PMID: 32365938 DOI: 10.3390/nano10050870] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
140 Glinka J, Ardiles V, Pekolj J, Mattera J, Sanchez Clariá R, de Santibañes E, de Santibañes M. Liver transplantation for non-resectable colorectal liver metastasis: where we are and where we are going. Langenbecks Arch Surg 2020;405:255-64. [PMID: 32333096 DOI: 10.1007/s00423-020-01883-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
141 Chen H, Cheng H, Dai Q, Cheng Y, Zhang Y, Li D, Sun Y, Mao J, Ren K, Chu C, Liu G. A superstable homogeneous lipiodol-ICG formulation for locoregional hepatocellular carcinoma treatment.J Control Release. 2020;323:635-643. [PMID: 32302761 DOI: 10.1016/j.jconrel.2020.04.021] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 12.3] [Reference Citation Analysis]
142 Guo J, Shirozu K, Akahoshi T, Mizuta Y, Murata M, Yamaura K. The farnesyltransferase inhibitor tipifarnib protects against autoimmune hepatitis induced by Concanavalin A. Int Immunopharmacol 2020;83:106462. [PMID: 32251961 DOI: 10.1016/j.intimp.2020.106462] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
143 Lee SK, Jang JW, Nam H, Sung PS, Bae SH, Choi JY, Yoon SK. Successful Sequential Therapy Involving Regorafenib after Failure of Sorafenib in a Patient with Recurrent Hepatocellular Carcinoma after Liver Transplantation. J Liver Cancer 2020;20:84-89. [DOI: 10.17998/jlc.20.1.84] [Reference Citation Analysis]
144 Zhang W, Huang J, Tang Y, Yang Y, Hu H. Inhibition of fatty acid synthase (FASN) affects the proliferation and apoptosis of HepG2 hepatoma carcinoma cells via the β-catenin/C-myc signaling pathway. Ann Hepatol 2020;19:411-6. [PMID: 32536483 DOI: 10.1016/j.aohep.2020.03.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
145 Chagas AL, Mattos AA, Carrilho FJ, Bittencourt PL, Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma. BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arq Gastroenterol 2020;57:1-20. [PMID: 32294682 DOI: 10.1590/S0004-2803.202000000-20] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
146 Jia J, Nie Y, Geng L, Li J, Liu J, Peng Y, Huang J, Xie H, Zhou L, Zheng SS. Identification of HO-1 as a novel biomarker for graft acute cellular rejection and prognosis prediction after liver transplantation. Ann Transl Med 2020;8:221. [PMID: 32309368 DOI: 10.21037/atm.2020.01.59] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
147 Goldaracena N, Barbas AS. Living donor liver transplantation. Curr Opin Organ Transplant. 2019;24:131-137. [PMID: 30694993 DOI: 10.1097/mot.0000000000000610] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
148 Chotai P, Matsuoka L. Reassessing the role of liver transplantation for patients with metastatic colorectal cancer to the liver. Curr Opin Organ Transplant 2019;24:118-20. [PMID: 30694992 DOI: 10.1097/MOT.0000000000000611] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
149 Simoneau E, D'Angelica M, Halazun KJ. Liver transplantation for colorectal liver metastasis. Curr Opin Organ Transplant 2019;24:175-81. [PMID: 30839338 DOI: 10.1097/MOT.0000000000000623] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
150 Al-Ameri AAM, Wei X, Wen X, Wei Q, Guo H, Zheng S, Xu X. Systematic review: risk prediction models for recurrence of hepatocellular carcinoma after liver transplantation. Transpl Int 2020;33:697-712. [PMID: 31985857 DOI: 10.1111/tri.13585] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
151 Millson C, Considine A, Cramp ME, Holt A, Hubscher S, Hutchinson J, Jones K, Leithead J, Masson S, Menon K, Mirza D, Neuberger J, Prasad R, Pratt A, Prentice W, Shepherd L, Simpson K, Thorburn D, Westbrook R, Tripathi D. Adult liver transplantation: A UK clinical guideline - part 1: pre-operation. Frontline Gastroenterol 2020;11:375-84. [PMID: 32879721 DOI: 10.1136/flgastro-2019-101215] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
152 Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, Salgia R, Seetharam A, Sharma P, Sherman C, Tsoulfas G, Yao FY. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant 2020;20:333-47. [PMID: 31710773 DOI: 10.1111/ajt.15697] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 17.7] [Reference Citation Analysis]
153 Mehta N. Hepatocellular Carcinoma-How to Determine Therapeutic Options. Hepatol Commun 2020;4:342-54. [PMID: 32140653 DOI: 10.1002/hep4.1481] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
154 Feng Y, Han Z, Feng Z, Wang B, Cheng H, Yang L, Li Y, Gu B, Li X, Li Y, Li Y, Wang C, Chen H. Approaching treatment for immunological rejection of living-donor liver transplantation in rats. BMC Gastroenterol 2020;20:7. [PMID: 31931737 DOI: 10.1186/s12876-019-1130-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
155 Bi J, Yang L, Wang T, Zhang J, Li T, Ren Y, Wang M, Chen X, Lv Y, Wu R. Irisin Improves Autophagy of Aged Hepatocytes via Increasing Telomerase Activity in Liver Injury. Oxid Med Cell Longev 2020;2020:6946037. [PMID: 31976032 DOI: 10.1155/2020/6946037] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
156 Tokmak S. Hepatocellular Carcinoma with Increased AFP Levels and Extrahepatic Manifestation after Liver Transplantation: A Case of Late-Onset Recurrence. Düzce Tıp Fakültesi Dergisi 2019. [DOI: 10.18678/dtfd.653558] [Reference Citation Analysis]
157 Wang W, Chen G, Wang B, Yuan Z, Liu G, Niu B, Chen Y, Zhou S, He J, Xue H. Long non-coding RNA BZRAP1-AS1 silencing suppresses tumor angiogenesis in hepatocellular carcinoma by mediating THBS1 methylation. J Transl Med 2019;17:421. [PMID: 31847842 DOI: 10.1186/s12967-019-02145-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
158 Yang K, Sung PS, You YK, Kim DG, Oh JS, Chun HJ, Jang JW, Bae SH, Choi JY, Yoon SK. Pathologic complete response to chemoembolization improves survival outcomes after curative surgery for hepatocellular carcinoma: predictive factors of response. HPB (Oxford) 2019;21:1718-26. [PMID: 31171489 DOI: 10.1016/j.hpb.2019.04.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
159 Al-Ameri AAM, Wei X, Lin L, Shao Z, Guo H, Xie H, Zhou L, Zheng S, Xu X. Preoperative risk stratification for early recurrence of HBV-related hepatocellular carcinoma after deceased donor liver transplantation: a five-eight model development and validation. BMC Cancer. 2019;19:1136. [PMID: 31752756 DOI: 10.1186/s12885-019-6343-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
160 Gorgen A, Prediger C, Prediger JE, Chedid MF, Backes AN, de Araujo A, Grezzana-Filho TJM, Leipnitz I, Chedid AD, Alvares-da-Silva MR, Sapisochin G, Kruel CRP. Serum Factor V Is a Continuous Biomarker of Graft Dysfunction and a Predictor of Graft Loss After Liver Transplantation. Transplantation 2019;103:944-51. [PMID: 30130328 DOI: 10.1097/TP.0000000000002429] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
161 Seydi E, Rahimpour Z, Salimi A, Pourahmad J. Selective toxicity of chrysin on mitochondria isolated from liver of a HCC rat model. Bioorg Med Chem. 2019;27:115163. [PMID: 31708277 DOI: 10.1016/j.bmc.2019.115163] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
162 Hu B, Yang X, Sang X. Liver graft rejection following immune checkpoint inhibitors treatment: a review. Med Oncol 2019;36. [DOI: 10.1007/s12032-019-1316-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
163 Kornberg A, Witt U, Schernhammer M, Kornberg J, Müller K, Friess H, Thrum K. The role of preoperative albumin‐bilirubin grade for oncological risk stratification in liver transplant patients with hepatocellular carcinoma. J Surg Oncol 2019;120:1126-36. [DOI: 10.1002/jso.25721] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
164 D'Souza JC, Sultan LR, Hunt SJ, Gade TP, Karmacharya MB, Schultz SM, Brice AK, Wood AKW, Sehgal CM. Microbubble-enhanced ultrasound for the antivascular treatment and monitoring of hepatocellular carcinoma. Nanotheranostics 2019;3:331-41. [PMID: 31687321 DOI: 10.7150/ntno.39514] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
165 D'souza JC, Sultan LR, Hunt SJ, Karmacharya MB, Brice AK, Wood AA, Sehgal CM. Multimodal Sonographic Assessment of Hepatocellular Carcinoma Response to Antivascular Therapy. 2019 IEEE International Ultrasonics Symposium (IUS) 2019. [DOI: 10.1109/ultsym.2019.8926209] [Reference Citation Analysis]
166 Gorgen A, Rosales R, Sadler E, Beecroft R, Knox J, Dawson LA, Ghanekar A, Grant D, Greig PD, Sapisochin G. Patterns and Predictors of Mortality After Waitlist Dropout of Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. Transplantation 2019;103:2136-43. [DOI: 10.1097/tp.0000000000002616] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
167 Chagas AL, Felga GEG, Diniz MA, Silva RF, Mattos AA, Silva RCMA, Boin IFSF, Garcia JHP, Lima AS, Coelho JCU, Bittencourt PL, Alves VAF, D'Albuquerque LAC, Carrilho FJ; Brazilian HCC Study Group. Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: clinical profile and prognostic factors of survival. Eur J Gastroenterol Hepatol 2019;31:1148-56. [PMID: 31247632 DOI: 10.1097/MEG.0000000000001448] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
168 Al-Ameri AAM, Wei X, Liu P, Lin L, Shao Z, Xie H, Zhou L, Zheng S, Xu X. Prediction of Early Recurrence of Hepatocellular Carcinoma in Patients with Cirrhosis Who Had Received Deceased Donor Liver Transplantation: A Multicenter Study. Ann Transplant 2019;24:489-98. [PMID: 31427563 DOI: 10.12659/AOT.917296] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
169 Abreu P, Gorgen A, Oldani G, Hibi T, Sapisochin G. Recent advances in liver transplantation for cancer: The future of transplant oncology. JHEP Rep 2019;1:377-91. [PMID: 32039389 DOI: 10.1016/j.jhepr.2019.07.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
170 Jiang Y, Han QJ, Zhang J. Hepatocellular carcinoma: Mechanisms of progression and immunotherapy. World J Gastroenterol 2019; 25(25): 3151-3167 [PMID: 31333308 DOI: 10.3748/wjg.v25.i25.3151] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 54] [Article Influence: 13.5] [Reference Citation Analysis]
171 Williams CH, Hickle K, Bakke K, Jamshed S, Bozorgzadeh A. Hepatic Epithelioid Angiomyolipoma Treated with Laparoscopic Resection: Case Report and Review of the Literature. Case Reports Hepatol 2019;2019:2362618. [PMID: 31355023 DOI: 10.1155/2019/2362618] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
172 Yadav DK, Hua YF, Bai X, Lou J, Que R, Gao S, Zhang Y, Wang J, Xie Q, Edoo MIA, Chutturghoon VK, Liang T. ABO-Incompatible Adult Living Donor Liver Transplantation in the Era of Rituximab: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract. 2019;2019:8589402. [PMID: 31285743 DOI: 10.1155/2019/8589402] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
173 Chen CP. Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma. J Clin Transl Hepatol. 2019;7:183-190. [PMID: 31293919 DOI: 10.14218/jcth.2018.00060] [Cited by in Crossref: 15] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
174 Doyle A, Gorgen A, Muaddi H, Aravinthan AD, Issachar A, Mironov O, Zhang W, Kachura J, Beecroft R, Cleary SP, Ghanekar A, Greig PD, McGilvray ID, Selzner M, Cattral MS, Grant DR, Lilly LB, Selzner N, Renner EL, Sherman M, Sapisochin G. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. J Hepatol 2019;70:866-73. [PMID: 30615906 DOI: 10.1016/j.jhep.2018.12.027] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 15.0] [Reference Citation Analysis]
175 Lange N, Dufour JF. Changing Epidemiology of HCC: How to Screen and Identify Patients at Risk? Dig Dis Sci 2019;64:903-9. [PMID: 30863952 DOI: 10.1007/s10620-019-05515-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
176 Iesari S, Inostroza Núñez ME, Rico Juri JM, Ciccarelli O, Bonaccorsi-Riani E, Coubeau L, Laterre PF, Goffette P, De Reyck C, Lengelé B, Gianello P, Lerut J. Adult-to-adult living-donor liver transplantation: The experience of the Université catholique de Louvain. Hepatobiliary Pancreat Dis Int 2019;18:132-42. [PMID: 30850341 DOI: 10.1016/j.hbpd.2019.02.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
177 Yoon YI, Lee SG. Living Donor Liver Transplantation for Hepatocellular Carcinoma: An Asian Perspective. Dig Dis Sci 2019;64:993-1000. [PMID: 30895483 DOI: 10.1007/s10620-019-05551-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
178 Freeman AJ, Sellers ZM, Mazariegos G, Kelly A, Saiman L, Mallory G, Ling SC, Narkewicz MR, Leung DH. A Multidisciplinary Approach to Pretransplant and Posttransplant Management of Cystic Fibrosis-Associated Liver Disease. Liver Transpl 2019;25:640-57. [PMID: 30697907 DOI: 10.1002/lt.25421] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
179 Foerster F, Hoppe-Lotichius M, Vollmar J, Marquardt JU, Weinmann A, Wörns MA, Otto G, Zimmermann T, Galle PR. Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre. United European Gastroenterol J 2019;7:838-49. [PMID: 31316788 DOI: 10.1177/2050640619840221] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
180 Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. Hepatology 2019;69:1193-205. [PMID: 30548884 DOI: 10.1002/hep.30413] [Cited by in Crossref: 19] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
181 Wong TCL, Ng KKC, Fung JYY, Chan AAC, Cheung T, Chok KSH, Dai JWC, Lo C. Long-Term Survival Outcome Between Living Donor and Deceased Donor Liver Transplant for Hepatocellular Carcinoma: Intention-to-Treat and Propensity Score Matching Analyses. Ann Surg Oncol 2019;26:1454-62. [DOI: 10.1245/s10434-019-07206-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
182 Sanduzzi-Zamparelli M, Díaz-Gonzalez Á, Reig M. New Systemic Treatments in Advanced Hepatocellular Carcinoma. Liver Transpl 2019;25:311-22. [PMID: 30317696 DOI: 10.1002/lt.25354] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
183 Shimamura T, Akamatsu N, Fujiyoshi M, Kawaguchi A, Morita S, Kawasaki S, Uemoto S, Kokudo N, Hasegawa K, Ohdan H, Egawa H, Furukawa H, Todo S;  Japanese Liver Transplantation Society. Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule - a retrospective study. Transpl Int. 2019;32:356-368. [PMID: 30556935 DOI: 10.1111/tri.13391] [Cited by in Crossref: 55] [Cited by in F6Publishing: 61] [Article Influence: 13.8] [Reference Citation Analysis]
184 Bi Y, Li J, Yang Y, Wang Q, Wang Q, Zhang X, Dong G, Wang Y, Duan Z, Shu Z, Liu T, Chen Y, Zhang K, Hong F. Human liver stem cells attenuate concanavalin A-induced acute liver injury by modulating myeloid-derived suppressor cells and CD4+ T cells in mice. Stem Cell Res Ther 2019;10:22. [PMID: 30635035 DOI: 10.1186/s13287-018-1128-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
185 Bhatti ABH, Dar FS, Qureshi AI, Khan NY, Zia HH, Haider S, Shah NH, Rana A. Living Donor Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience from Pakistan. J Clin Exp Hepatol 2019;9:704-9. [PMID: 31889751 DOI: 10.1016/j.jceh.2019.04.052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
186 Kornberg A, Schernhammer M, Kornberg J, Friess H, Thrum K. Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma. Dig Dis Sci 2019;64:269-80. [PMID: 30259282 DOI: 10.1007/s10620-018-5296-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
187 O'donoghue P, O'beirne J, Malago M, Woodrow L, Imber C, Sharma D. Clinical nurse specialist role in setting up a joint hepatocellular carcinoma clinic at a specialist liver unit. Gastrointestinal Nursing 2018;16:S20-S28. [DOI: 10.12968/gasn.2018.16.sup10.s20] [Reference Citation Analysis]
188 Lv Y, Wei W, Huang Z, Chen Z, Fang Y, Pan L, Han X, Xu Z. Long non-coding RNA expression profile can predict early recurrence in hepatocellular carcinoma after curative resection. Hepatol Res 2018;48:1140-8. [PMID: 29924905 DOI: 10.1111/hepr.13220] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
189 Rodríguez-perálvarez M, Guerrero M, Barrera L, Ferrín G, Álamo JM, Ayllón MD, Artacho GS, Montero JL, Briceño J, Bernal C, Padillo J, Marín-gómez LM, Pascasio JM, Poyato A, Gómez-bravo MA, De la Mata M. Impact of Early Initiated Everolimus on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation. Transplantation 2018;102:2056-64. [DOI: 10.1097/tp.0000000000002270] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
190 Qu Z, Krauth C, Amelung VE, Kaltenborn A, Gwiasda J, Harries L, Beneke J, Schrem H, Liersch S. Decision modelling for economic evaluation of liver transplantation. World J Hepatol 2018; 10(11): 837-848 [PMID: 30533184 DOI: 10.4254/wjh.v10.i11.837] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
191 Hibi T, Sapisochin G. What is transplant oncology? Surgery. 2019;165:281-285. [PMID: 30471780 DOI: 10.1016/j.surg.2018.10.024] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 6.6] [Reference Citation Analysis]
192 Zhang N, Jin W, Zhou S, Yang JD, Harmsen WS, Giama NH, Wongjarupong N, Heimbach JK, Watt KD, Malhi H, Therneau TM, Roberts LR. Hypothyroidism is associated with worse outcomes of hepatocellular carcinoma patients after liver transplantation. Cancer Med 2018;7:5870-8. [PMID: 30453389 DOI: 10.1002/cam4.1797] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
193 Liu H, Cen D, Yu Y, Wang Y, Liang X, Lin H, Cai X. Does fibrosis have an impact on survival of patients with hepatocellular carcinoma: evidence from the SEER database? BMC Cancer 2018;18:1125. [PMID: 30445928 DOI: 10.1186/s12885-018-4996-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
194 Schöning W, Öllinger R, Schmelzle M, Pratschke J. [Frontiers in liver transplantation in indication and techniques]. Chirurg 2019;90:102-9. [PMID: 30413847 DOI: 10.1007/s00104-018-0761-8] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
195 Désert R, Nieto N, Musso O. Dimensions of hepatocellular carcinoma phenotypic diversity. World J Gastroenterol 2018; 24(40): 4536-4547 [PMID: 30386103 DOI: 10.3748/wjg.v24.i40.4536] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
196 Afroz F, Kist A, Hua J, Zhou Y, Sokoya EM, Padbury R, Nieuwenhuijs V, Barritt G. Rapamycin induces the expression of heme oxygenase-1 and peroxyredoxin-1 in normal hepatocytes but not in tumorigenic liver cells.Exp Mol Pathol. 2018;105:334-344. [PMID: 30290159 DOI: 10.1016/j.yexmp.2018.09.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
197 Ma Z, Yan H, Wang Y, Yang Y, Li X, Shi A, Jing-wen X, Yu-bao L, Li L, Wang X. Proteomics analysis demonstrating rosmarinic acid suppresses cell growth by blocking the glycolytic pathway in human HepG2 cells. Biomedicine & Pharmacotherapy 2018;105:334-49. [DOI: 10.1016/j.biopha.2018.05.129] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
198 Saberi B, Garonzik-Wang J, Ma M, Ajayi T, Kim A, Luu H, Jakhete N, Pustavoitau A, Anders RA, Georgiades C, Kamel I, Ottmann S, Philosophe B, Cameron AM, Gurakar A. Accuracy of Milan, University of California San Francisco, and Up-To-7 Criteria in Predicting Tumor Recurrence Following Deceased-Donor Liver Transplant in Patients With Hepatocellular Carcinoma. Exp Clin Transplant 2020;18:463-9. [PMID: 30084757 DOI: 10.6002/ect.2017.0288] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
199 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 3722] [Cited by in F6Publishing: 3826] [Article Influence: 744.4] [Reference Citation Analysis]
200 Song T, Wang C, Guo C, Liu Q, Zheng X. Pentraxin 3 overexpression accelerated tumor metastasis and indicated poor prognosis in hepatocellular carcinoma via driving epithelial-mesenchymal transition. J Cancer 2018;9:2650-8. [PMID: 30087705 DOI: 10.7150/jca.25188] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
201 Lau KCK, Osiowy C, Giles E, Lusina B, van Marle G, Burak KW, Coffin CS. Deep sequencing shows low-level oncogenic hepatitis B virus variants persists post-liver transplant despite potent anti-HBV prophylaxis. J Viral Hepat 2018;25:724-32. [PMID: 29316067 DOI: 10.1111/jvh.12860] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
202 Kim AY, Sinn DH, Jeong WK, Kim YK, Kang TW, Ha SY, Park CK, Choi GS, Kim JM, Kwon CHD, Joh JW, Kim MJ, Sohn I, Jung SH, Paik SW, Lee WJ. Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma. J Hepatol 2018;68:1144-52. [PMID: 29410377 DOI: 10.1016/j.jhep.2018.01.024] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
203 Foerster F, Mittler J, Darstein F, Heise M, Marquardt JU, Wörns MA, Weinmann A, Sälter L, Hoppe-Lotichius M, Heinrich S, Kloeckner R, Pitton MB, Schattenberg JM, Sprinzl MF, Düber C, Otto G, Lang H, Galle PR, Zimmermann T. Recipient liver function before liver transplantation influences post-transplantation survival in patients with HCC. Eur J Intern Med 2018;55:57-65. [PMID: 29859798 DOI: 10.1016/j.ejim.2018.05.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
204 Montano-Loza AJ, Mazurak VC, Ebadi M, Meza-Junco J, Sawyer MB, Baracos VE, Kneteman N. Visceral adiposity increases risk for hepatocellular carcinoma in male patients with cirrhosis and recurrence after liver transplant. Hepatology 2018;67:914-23. [PMID: 29023899 DOI: 10.1002/hep.29578] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
205 Mehta N, Yao FY. Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)? Liver Transpl 2018;24:327-9. [PMID: 29351366 DOI: 10.1002/lt.25017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
206 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet 2018;391:1301-14. [DOI: 10.1016/s0140-6736(18)30010-2] [Cited by in Crossref: 2447] [Cited by in F6Publishing: 2257] [Article Influence: 489.4] [Reference Citation Analysis]
207 Goldaracena N, Gorgen A, Sapisochin G. Current status of liver transplantation for cholangiocarcinoma. Liver Transpl 2018;24:294-303. [PMID: 29024405 DOI: 10.1002/lt.24955] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 11.6] [Reference Citation Analysis]
208 Muaddi H, Al-Adra DP, Beecroft R, Ghanekar A, Moulton CA, Doyle A, Selzner M, Wei A, McGilvray ID, Gallinger S, Grant DR, Cattral MS, Greig PD, Kachura J, Cleary SP, Sapisochin G. Liver Transplantation is Equally Effective as a Salvage Therapy for Patients with Hepatocellular Carcinoma Recurrence Following Radiofrequency Ablation or Liver Resection with Curative Intent. Ann Surg Oncol. 2018;25:991-999. [PMID: 29327179 DOI: 10.1245/s10434-017-6329-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
209 Gorgen A, Muaddi H, Zhang W, McGilvray I, Gallinger S, Sapisochin G. The New Era of Transplant Oncology: Liver Transplantation for Nonresectable Colorectal Cancer Liver Metastases. Can J Gastroenterol Hepatol. 2018;2018:9531925. [PMID: 29623268 DOI: 10.1155/2018/9531925] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
210 Huang LF, Wan P, Xu DW, Jeong S, Feng MX, Zhang JJ, Xia Q. Nomogram predicting pulmonary metastasis of hepatocellular carcinoma after liver transplantation. Oncotarget 2018;9:2425-34. [PMID: 29416782 DOI: 10.18632/oncotarget.23418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
211 Ghinolfi D, Rreka E, Pezzati D, Filipponi F, De Simone P. Perfusion machines and hepatocellular carcinoma: a good match between a marginal organ and an advanced disease? Transl Gastroenterol Hepatol 2017;2:87. [PMID: 29264425 DOI: 10.21037/tgh.2017.10.01] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
212 Désert R, Rohart F, Canal F, Sicard M, Desille M, Renaud S, Turlin B, Bellaud P, Perret C, Clément B, Lê Cao KA, Musso O. Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection. Hepatology 2017;66:1502-18. [PMID: 28498607 DOI: 10.1002/hep.29254] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 10.3] [Reference Citation Analysis]
213 Kornberg A, Witt U, Schernhammer M, Kornberg J, Ceyhan GO, Mueller K, Friess H, Thrum K. Combining 18F-FDG positron emission tomography with Up-to-seven criteria for selecting suitable liver transplant patients with advanced hepatocellular carcinoma. Sci Rep. 2017;7:14176. [PMID: 29074969 DOI: 10.1038/s41598-017-14430-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
214 Kalisvaart M, de Haan JE, Polak WG, Metselaar HJ, Wijnhoven BPL, IJzermans JNM, de Jonge J. Comparison of Postoperative Outcomes Between Donation After Circulatory Death and Donation After Brain Death Liver Transplantation Using the Comprehensive Complication Index. Ann Surg. 2017;266:772-778. [PMID: 28742700 DOI: 10.1097/sla.0000000000002419] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 7.3] [Reference Citation Analysis]
215 Peloso A, Oldani G. Enlarged selection criteria for hepatocellular cancer: is the upper limit needed? Transl Gastroenterol Hepatol 2017;2:73. [PMID: 29034346 DOI: 10.21037/tgh.2017.09.02] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
216 Wang W, Zhang M, Peng Y, He J. Ubiquitin Associated Protein 2-Like (UBAP2L) Overexpression in Patients with Hepatocellular Carcinoma and its Clinical Significance. Med Sci Monit 2017;23:4779-88. [PMID: 28981479 DOI: 10.12659/msm.907071] [Cited by in Crossref: 8] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
217 Akkız H. New Paradigm: Adaptive Approach. J Gastrointest Canc 2017;48:219-221. [DOI: 10.1007/s12029-017-9956-3] [Reference Citation Analysis]
218 Oldani G, Peloso A, Lacotte S, Meier R, Toso C. Xenogeneic chimera-Generated by blastocyst complementation-As a potential unlimited source of recipient-tailored organs. Xenotransplantation 2017;24. [PMID: 28736957 DOI: 10.1111/xen.12327] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
219 Rowe IA. Understanding the benefits and risks in donor liver allocation. Clin Liver Dis (Hoboken) 2017;10:21-4. [PMID: 30992753 DOI: 10.1002/cld.645] [Reference Citation Analysis]
220 Allaire M, Nault J. Advances in management of hepatocellular carcinoma. Current Opinion in Oncology 2017;29:288-95. [DOI: 10.1097/cco.0000000000000378] [Cited by in Crossref: 21] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
221 Fang M, Zheng WJ, Yao M, Dong ZZ, Yao DF. Novel specific markers for hepatocellular carcinoma: Perspective on clinical applications. Shijie Huaren Xiaohua Zazhi 2017; 25(10): 865-873 [DOI: 10.11569/wcjd.v25.i10.865] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]